-
1 Comment
Bio-Techne Corporation is currently in a long term uptrend where the price is trading 26.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.8.
Bio-Techne Corporation's total revenue rose by 21.3% to $224M since the same quarter in the previous year.
Its net income has dropped by 52.9% to $56M since the same quarter in the previous year.
Finally, its free cash flow grew by 137.9% to $133M since the same quarter in the previous year.
Based on the above factors, Bio-Techne Corporation gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
ISIN | US09073M1045 |
CurrencyCode | USD |
Exchange | NASDAQ |
Dividend Yield | 0.4% |
---|---|
PE Ratio | 50.76 |
Market Cap | 13B |
Target Price | 101.12 |
Beta | 1.24 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TECH using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024